Lipid risk factors and the regression of atherosclerosis.
Angiographically monitored clinical trials of antilipidemic therapy have demonstrated that the progression of atherosclerosis may be slowed or even reversed. The clinical benefit observed in these trials strengthens the rationale for aggressive therapy in patients with known atherosclerotic disease. Additionally, these trials have provided further insight on the basis of clinical events and the risk factors associated with progression.
Gotto
A M
AM
Baylor College of Medicine, Houston, Texas 77030, USA.
D000792:Angiography; D001161:Arteriosclerosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D012074:Remission Induction; D012307:Risk Factors
D000960:Hypolipidemic Agents; D008055:Lipids